Amyris, Inc. (NASDAQ:AMRS), a leading renewable chemicals and fuels company, today announced financial results for the fourth quarter and year ended December 31, 2011.
“2011 was a year of accomplishment and learning. We opened three facilities on three continents to produce initial volumes of Biofene®, our renewable farnesene, and have now produced over 1.3 million liters of Biofene, which we are selling initially as squalane and diesel,” said John Melo, CEO of Amyris. “We have proven that our technology produces renewable hydrocarbons at scale and continue to meet our current customer demand for quality and performance. With the additional financing we have secured, we have a strong position to ramp our production to meet the needs of an expanding group of customers,” he added.
In a separate release today, Amyris also announced it has closed a $58.7 million private placement of its common stock at market value and issued a $25 million five-year convertible debt offering to an institutional investor.
Aggregate revenues for year ended December 31, 2011 were $147.0 million versus $80.3 million in the prior year, with cost of products sold of $155.6 million versus $70.5 million. Research and development expense increased to $87.3 million from $55.2 million and sales, general and administrative expense increased to $83.2 million from $40.4 million. The 2011 GAAP net loss attributable to Amyris, Inc. common stockholders was $178.9 million compared with $123.9 million in the prior year. On a non-GAAP basis, excluding stock-based compensation expense and non-cash beneficial conversion feature charge booked in the third quarter of 2010, the net loss attributable to Amyris, Inc. common stockholders was $153.4 million compared to $71.4 million in the prior year. A reconciliation of GAAP to non-GAAP results is included in this release.
Aggregate revenues for the quarter ended December 31, 2011 were $41.5 million versus $29.7 million in the fourth quarter of 2010, and cost of products sold was $56.4 million versus $27.5 million. Research and development expense increased to $20.7 million from $17.0 million, and sales, general and administrative expense increased to $23.8 million from $11.0 million. Fourth quarter 2011 GAAP net loss attributable to common stockholders was $59.4 million compared with $25.6 million in the same quarter of 2010.